Lv52
928 积分 2024-11-01 加入
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer
2小时前
已完结
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
9天前
已完结
Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability
30天前
已完结
Structure–activity relationships of KRAS-G12D inhibitors for pancreatic cancer
1个月前
已完结
Targeting the SHOC2–RAS interaction in RAS-mutant cancers
1个月前
已完结
Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor
2个月前
已关闭
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
3个月前
已完结
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC
3个月前
已完结
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
4个月前
已完结
Novel Macrocyclic NLRP3 Inhibitors
8个月前
已完结
皖公网安备34019202002308
